Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 6, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and share ownership disclosures.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On October 5, 2004, Abacus (GSK) Trustees Limited transferred 10,228 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on October 6, 2004.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe—are interested in the shares held in the GSK Trust in the same manner as other employees. No specific risks, contingencies, or unusual financial items are detailed in this text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to the transfer of 10,228 shares.
- Confirm the specific allocation of the transferred shares among the three named directors.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.
- Check subsequent filings for any further changes in director shareholdings.